Project Panacea: Modeling the Next Step in DCIS-to-Invasive Breast Cancer Translation
top of page
Search

Project Panacea: Modeling the Next Step in DCIS-to-Invasive Breast Cancer Translation

  • 8 hours ago
  • 2 min read

At Rubix LS, Project Panacea, in conjunction with TheraSyn Bio, is being developed around a specific translational question: can a topical, locally acting therapeutic approach generate measurable biological activity in breast tissue while limiting systemic exposure?


That question matters because the first disease context for Panacea is not broad metastatic breast cancer. The clearest translational entry point is ductal carcinoma in situ, or DCIS, and the biological bridge from DCIS toward invasive ductal carcinoma.


DCIS presents a unique evidence challenge. Some lesions remain indolent, while others recur or progress toward invasive disease. Current clinical decision-making is shaped by histology, receptor status, surgery, radiotherapy, and endocrine therapy, but the field still needs better ways to distinguish lesions that may remain stable from those with higher progression risk.


Our new scientific and technical white paper outlines how Rubix LS is approaching that challenge through tissue-confirmed pharmacology.


The paper focuses on several core technical questions:


  • Can Panacea reach breast tissue through topical delivery?

  • Can it produce measurable change in Ki-67, a key proliferation marker?

  • Can changes in p-Akt, cleaved caspase-3, and immune-cell presence help clarify mechanism?

  • How should ER, PR, and HER2 status shape response interpretation?

  • How does DCIS biology inform translation into early invasive breast cancer contexts?

  • How can environmental and patient-condition variables affect how response is modeled?


The report also includes a 100-condition in-silico simulation layer. These synthetic digital profiles were designed from diverse patient-condition representation and modeled across biological, environmental, and pharmacodynamic variables. The purpose is not to claim clinical efficacy. The purpose is to pressure-test how environmental exacerbation, nutritional deterioration, heat-sink burden, exposure pressure, care-access friction, and chronic stress may alter the interpretation of tissue responses.


Environmental exacerbation changes interpretation, not only access. In-silico simulation of 100 diverse digital condition profiles shows how predicted Ki-67 response varies by environmental-exacerbation index and tissue-confirmed pharmacology score.

This is the next step in Rubix LS's approach to evidence generation. We are not only asking whether an investigational therapy can create a biological signal. We are asking whether that signal can be understood across the real patient conditions that shape disease expression, access, and translational relevance.


The white paper includes:


  1. A DCIS-first development rationale

  2. A biomarker stack led by Ki-67

  3. ER/PR/HER2 receptor-context stratification

  4. p-Akt and PI3K-Akt pathway logic

  5. Cleaved caspase-3 and apoptosis signaling

  6. Immune microenvironment considerations

  7. Preclinical proof-of-concept interpretation

  8. A 100-condition in-silico environmental simulation


Recommended next technical outputs for pre-IND, GLP dermal toxicology, CMC scale-up, maximal usage evaluation, and a presurgical window-of-opportunity study


Project Panacea remains investigational, and the simulation outputs are hypothesis-generating. But the direction is clear: the next phase of therapeutic development requires more than a molecule and a model. It requires evidence architecture that connects tissue biology, patient context, and translational decision-making.


Download the full white paper below.



bottom of page